Cargando…
Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition
Although mechanisms of acquired resistance of EGFR mutant non-small cell lung cancers to EGFR inhibitors have been identified, little is known about how resistant clones evolve during drug therapy. Here, we observe that acquired resistance caused by the T790M gatekeeper mutation can occur either by...
Autores principales: | Hata, Aaron N, Niederst, Matthew J, Archibald, Hannah L, Gomez-Caraballo, Maria, Siddiqui, Faria M, Mulvey, Hillary E, Maruvka, Yosef E, Ji, Fei, Bhang, Hyo-eun C, Radhakrishna, Viveksagar Krishnamurthy, Siravegna, Giulia, Hu, Haichuan, Raoof, Sana, Lockerman, Elizabeth, Kalsy, Anuj, Lee, Dana, Keating, Celina L, Ruddy, David A, Damon, Leah J, Crystal, Adam S, Costa, Carlotta, Piotrowska, Zofia, Bardelli, Alberto, Iafrate, Anthony J, Sadreyev, Ruslan I, Stegmeier, Frank, Getz, Gad, Sequist, Lecia V, Faber, Anthony C, Engelman, Jeffrey A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4900892/ https://www.ncbi.nlm.nih.gov/pubmed/26828195 http://dx.doi.org/10.1038/nm.4040 |
Ejemplares similares
-
RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer
por: Niederst, Matthew J., et al.
Publicado: (2015) -
Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant
non-small cell lung cancer
por: Raoof, Sana, et al.
Publicado: (2019) -
Genotyping cell-free tumor DNA in the blood to detect residual disease and drug resistance
por: Siravegna, Giulia, et al.
Publicado: (2014) -
Cardiac Risk-Informed Treatment of EGFR-Mutant Lung Cancer With Osimertinib
por: Piper-Vallillo, Andrew J., et al.
Publicado: (2019) -
Diffuse Lung Metastases in EGFR-Mutant Non-Small Cell Lung Cancer
por: Digumarthy, Subba R., et al.
Publicado: (2019)